This would suggest an increased use of chemotherapy near the end of life, which was identified in this study. The availability of new chemotherapeutic agents has caused a subsequent increase in the length of time patients are receiving chemotherapy with advanced NSCLC. Chemotherapy was given within 1 month and 2 weeks of death to 43% and 20% of patients, respectively. For patients receiving chemotherapy at the time of death, the mean line of therapy being given was second line. Jose MURILLO JR, Clinical Specialist II - Hematology / Oncology Cited by 140 of Houston Methodist Hospital, Houston (HOUSTONMETHODIST) Read 6. Patients received a mean of 6.1 cycles of chemotherapy. He attended and graduated from medical school in 2010, having over 11 years of diverse experience, especially in Family Practice. Twenty-six percent of patients received third-line therapy, while 10% received fourth-line therapy and 5% received fifth-line therapy or greater. Jose Murillo Jr., MD, is a Family Practice specialist in Miami Beach, Florida. Second-line therapy was given to 56% of patients. First-line chemotherapy included combination therapy in 84% of patients. He is rated 5 out of 5 by patients on CareDash and has received an. Forty percent of patients were >69 years of age and 35% had an Eastern Cooperative Oncology Group performance status score of > or =2. MD (he/him) is a highly-rated family physician in Pensacola, FL. Jose Murillo offers complete health care for individuals & families. The mean age was 67 years (median, 62 years) and 54% were male. Murillo is normally the initial point of contact for patients looking for general or primary medical treatment & can direct patients to a specialist when necessary. We report data from 10 community practices including 417 patients treated for advanced NSCLC in 2000-2003. Patient demographics, all chemotherapy including dose and schedule, and disease-related events were collected.
Patients who initiated chemotherapy in 2000-2003 were eligible. We conducted a retrospective chart review of expired advanced (stage IIIb/IV) NSCLC patients treated with chemotherapy. The availability of new chemotherapeutic agents has caused a subsequent increase in the length of time patients are receiving chemotherapy with advanced NSCLC. There are 40+ professionals named 'Murillo Jr', who use LinkedIn to exchange information, ideas, and opportunities.
Únete a Facebook para estar en contacto con Jose Murillo Guerrero y otras personas que tal vez. To characterize the chemotherapy given near the end of life to advanced non-small cell lung cancer (NSCLC) patients treated in the community oncology setting using a medical records database. View the profiles of professionals named 'Murillo Jr' on LinkedIn. Ver perfiles de personas llamadas Jose Murillo Guerrero.
0 kommentar(er)
